Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 126 publications
Central nervous system antituberculosis drug exposures in a rabbit model of tuberculous meningitis.
Journal: Antimicrobial agents and chemotherapy
Published: July 10, 2026
Cytochrome P450-Mediated Metabolism of Antimycobacterial Nα-Aroyl-N-aryl-phenylalanine Amides.
Journal: ACS infectious diseases
Published: June 02, 2026
Design, Synthesis and Biological Evaluation of Potent Piperazine-Based BioA Inhibitors Targeting Biotin Biosynthesis in Mycobacterium tuberculosis.
Journal: Journal of medicinal chemistry
Published: April 22, 2026
Impact of High-Dose Rifampicin on Linezolid Pharmacokinetics in Tuberculous Meningitis.
Journal: Open forum infectious diseases
Published: February 17, 2026
Same class, different activity: Delamanid and pretomanid have comparable bactericidal activity but pretomanid potently inhibits Mycobacterium tuberculosis ribosomal rRNA synthesis.
Journal: bioRxiv : the preprint server for biology
Published: January 09, 2026
PET/CT imaging of tuberculosis lung lesions in marmosets treated with different drug regimens aligns with human clinical outcomes.
Journal: Science translational medicine
Published: January 07, 2026
Triazole Resistance and Misidentification of Aspergillus tubingensis in Southern California.
Journal: JAMA network open
Published: December 04, 2025
Structure-Guided Development of a Potent BioA Inhibitor Validates Biotin Synthesis Inhibition as a Therapeutic Strategy for Tuberculosis.
Journal: bioRxiv : the preprint server for biology
Published: October 03, 2025
Sterilizing activity of spectinamide MBX-4888A when replacing linezolid in the Nix-TB regimen in the relapsing BALB/c mouse model of tuberculosis.
Journal: Antimicrobial agents and chemotherapy
Published: September 30, 2025
Sterilizing activity of spectinamide MBX-4888A when replacing linezolid in the Nix-TB regimen in the relapsing BALB/c mouse model of tuberculosis.
Journal: bioRxiv : the preprint server for biology
Published: August 13, 2025
Next-generation rifamycins for the treatment of mycobacterial infections.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: May 01, 2025
Physiologic recovery of Mycobacterium tuberculosis from drug injury: A molecular study of post antibiotic effect in vitro and in vivo.
Journal: PLoS pathogens
Published: April 24, 2025
Last Updated: 09/26/2026